{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+Part+1+Group+4&page=2",
    "query": {
      "intervention": "Placebo - Part 1 Group 4",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+Part+1+Group+4&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T02:39:15.097Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01686555",
      "title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "ABT-199",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 97,
      "start_date": "2012-11",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2017-11-20",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 11,
      "location_summary": "Clearwater, Florida • DeBary, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeBary",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01686555"
    },
    {
      "nct_id": "NCT06686121",
      "title": "Improving Mobility After Revascularization in Peripheral Artery Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Artery Disease",
        "Intermittent Claudication",
        "Peripheral Vascular Disease",
        "Mobility Limitation",
        "Revascularization"
      ],
      "interventions": [
        {
          "name": "Home Based Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Nitrate Rich Beetroot Juice",
          "type": "DRUG"
        },
        {
          "name": "Attention Control",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo Beetroot Juice Without Nitrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2025-08-04",
      "completion_date": "2032-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Downey, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686121"
    },
    {
      "nct_id": "NCT01210495",
      "title": "Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Axitinib (AG-013736)",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2010-12-06",
      "completion_date": "2016-12-20",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 13,
      "location_summary": "Berkeley, California • La Jolla, California • Orange, California + 7 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01210495"
    },
    {
      "nct_id": "NCT02542605",
      "title": "To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PACAP-38 Challenge Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 35,
      "start_date": "2015-11-11",
      "completion_date": "2017-11-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02542605"
    },
    {
      "nct_id": "NCT01521143",
      "title": "Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Cvac",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prima BioMed Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 91,
      "start_date": "2012-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-12-14",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521143"
    },
    {
      "nct_id": "NCT03100149",
      "title": "A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "RO7046015",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 316,
      "start_date": "2017-06-27",
      "completion_date": "2031-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03100149"
    },
    {
      "nct_id": "NCT02623205",
      "title": "Advancing Personalized Antidepressant Treatment Using PET/MRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stony Brook University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2015-05",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 1,
      "location_summary": "Stony Brook, New York",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02623205"
    },
    {
      "nct_id": "NCT02505542",
      "title": "Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Axial Spondyloarthrithis",
        "Ankylosing Spondylitis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB BIOSCIENCES GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 736,
      "start_date": "2015-07",
      "completion_date": "2019-04",
      "has_results": true,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02505542"
    },
    {
      "nct_id": "NCT03571594",
      "title": "A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acromegaly"
      ],
      "interventions": [
        {
          "name": "ONO-5788",
          "type": "DRUG"
        },
        {
          "name": "ONO-5788 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ono Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2018-06-07",
      "completion_date": "2019-05-16",
      "has_results": false,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03571594"
    },
    {
      "nct_id": "NCT01121302",
      "title": "Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tolerability"
      ],
      "interventions": [
        {
          "name": "AZD5213",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 88,
      "start_date": "2010-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-28",
      "last_synced_at": "2026-09-30T02:39:15.097Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01121302"
    }
  ]
}